SINTX Technologies, Inc. reported third-quarter revenue of approximately $2.2 million versus $208,000, net loss of approximately $1.6 million, down 55%, and completed the limited-use release of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System.
SINT · Sintx Technologies, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Despite the actions undertaken by management to improve liquidity and operating costs—including increased commercial activity, cost and pricing improvement initiatives, commercialization of newly cleared medical products, equity financing activities, proceeds from warrant exercises subsequent to quarter-end, and other working capital initiatives—management has concluded that substantial doubt remains regarding our ability to continue as a going concern for a period of one year from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
SINTX Technologies reported total revenue growth of 315% for the nine months ended September 30, 2026, while net loss was $7.1 million and operating cash use was $6.6 million; substantial doubt remains about its ability to continue as a going concern.
SINTX Technologies, Inc. will hold its annual meeting on December 9, 2026, to elect Mark Anderson and Gregg Honigblum as Class III directors through 2029, ratify Tanner LLP, approve advisory executive compensation, and authorize possible adjournments.
SINTX Technologies, Inc. received $2,014,645.22 from funded exercises and related exchanges involving 941,423 Class B warrant shares at $2.14 per share, issued 651,204 common shares and pre-funded warrants for 290,219 shares, and ended with no Class B warrants outstanding.
SINTX Technologies, Inc. reported preliminary, unaudited revenue of $2.2 million for the quarter ended September 30, 2026, including approximately $2.1 million in product sales. It intends to call Class B Warrants covering approximately 1.88 million shares.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SINT
this stock
Sintx Technologies, Inc.
|
$10.17M | -65.2% | -64.7% | — | 1.7% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 18
SINTX Technologies reported total revenue growth of 315% for the nine months ended September 30, 2026, while net loss was $7.1 million and operating cash use was $6.6 million; substantial doubt remains about its ability to continue as a going concern.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SINT | -13.8% | -22.7% | -44.7% | -20.9% | -65.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -16.4% | -21.5% | -45.2% | -20.7% | -75.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.